- Home
- RPD vs PHAR Comparison
RPD vs PHAR Comparison
Compare RPD & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPD | PHAR |
|---|---|---|
| Founded | 2000 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | RPD | PHAR |
|---|---|---|
| Price | $15.40 | $17.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 21 | 2 |
| Target Price | $24.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 1.1M | 24.5K |
| Earning Date | 02-11-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.35 | 0.00 |
| Revenue | ★ $858,667,000.00 | $362,274,000.00 |
| Revenue This Year | $2.62 | $25.19 |
| Revenue Next Year | $1.49 | $4.47 |
| P/E Ratio | ★ $44.24 | $3,041.40 |
| Revenue Growth | 3.08 | ★ 26.78 |
| 52 Week Low | $13.21 | $7.50 |
| 52 Week High | $41.38 | $18.30 |
Technical Indicators
Market Signals| Indicator | RPD | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 43.64 | 58.10 |
| Support Level | $15.06 | $16.98 |
| Resistance Level | $15.90 | $17.00 |
| Average True Range (ATR) | 0.46 | 0.69 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 15.93 | 82.04 |
Price Performance
Historical ComparisonAbout RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.